TD Asset Management Inc Has $45.60 Million Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• TD Asset Management Inc reduced its holdings in United Therapeutics by 1.7%, owning 147,911 shares valued at approximately $45.6 million as of the end of the most recent quarter.
• Multiple brokerages have adjusted their price targets on United Therapeutics, with Morgan Stanley lowering its target from $348.00 to $328.00, indicating a trend of decreasing valuations.
• Insiders, including EVP Paul A. Mahon, sold significant amounts of stock, with a total of 81,681 shares sold in the last three months, reflecting a 23.02% decrease in Mahon's ownership after selling $3.3 million worth of shares.

TD Asset Management Inc reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 1.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 147,911 shares of the biotechnology company's stock after selling 2,543 shares during the quarter. TD Asset Management Inc owned 0.33% of United Therapeutics worth $45,597,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Applied Finance Capital Management LLC grew its position in United Therapeutics by 3.7% in the first quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock valued at $349,000 after acquiring an additional 40 shares in the last quarter. Mediolanum International Funds Ltd grew its position in United Therapeutics by 192.2% in the first quarter. Mediolanum International Funds Ltd now owns 15,257 shares of the biotechnology company's stock valued at $4,683,000 after acquiring an additional 10,036 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its position in United Therapeutics by 20.1% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 100,854 shares of the biotechnology company's stock valued at $31,090,000 after acquiring an additional 16,849 shares in the last quarter. Longbow Finance SA acquired a new stake in United Therapeutics in the first quarter valued at approximately $3,461,000. Finally, Assetmark Inc. grew its position in United Therapeutics by 20.8% in the first quarter. Assetmark Inc. now owns 518,450 shares of the biotechnology company's stock valued at $159,823,000 after acquiring an additional 89,290 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on UTHR. Morgan Stanley lowered their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Bank of America reduced their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. UBS Group reduced their target price on United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research note on Monday, June 30th. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, Cantor Fitzgerald began coverage on United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $383.08.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $304.11, for a total transaction of $3,345,210.00. Following the transaction, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $11,185,469.91. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard Giltner sold 3,036 shares of the firm's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director directly owned 19,384 shares in the company, valued at $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,681 shares of company stock valued at $24,628,589 over the last three months. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Stock Down 0.2%

NASDAQ UTHR traded down $0.58 during trading hours on Tuesday, hitting $297.56. The company had a trading volume of 527,065 shares, compared to its average volume of 369,896. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The business has a fifty day simple moving average of $299.63 and a 200-day simple moving average of $314.91. The firm has a market cap of $13.42 billion, a P/E ratio of 11.87, a price-to-earnings-growth ratio of 6.50 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same period last year, the company earned $6.17 earnings per share. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. Equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.